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ABSTRACT
Objective: Many psychological and psychosocial interventions have been developed to treat regular
users of cannabis, but it is unclear which intervention(s) are the most effective. This article aims to
assess the effectiveness of psychological and psychosocial interventions for cannabis cessation, and
to outline priorities for future research. Methods: A systematic review of the scientific literature.
Eleven databases were searched in February 2014. Results: Twenty-six RCTs were identified; the
majority were considered to be at a high risk of bias. Cognitive behavioural therapy (CBT)
significantly improved outcomes compared with wait-list in five studies post-treatment, maintained
at 9 months in the one study with later follow-up. Studies of motivational interviewing (MI) or
motivational enhancement therapy (MET) gave mixed results, with some improvements over wait-
list while some comparisons were not significant. Four studies comparing CBT against MI/MET gave
mixed results; longer courses of CBT provided some improvements over shorter MI. Courses of
other types of therapy (social support groups and case management) gave similar improvements to
CBT. Vouchers for abstinence (contingency management) gave promising results in the short-term
and at follow-up. Conclusion: Studies were heterogeneous, covering a range of interventions,
comparators, populations and outcomes. CBT improved short-term outcomes in a clinically
dependent self-selected population of cannabis users. Brief MI improved short-term outcomes at
post-treatment in a younger non-clinically dependent population. There is some evidence that CBT
may be more effective than briefer MI interventions although results were mixed. Contingency
management may enhance long-term outcomes in combination with CBT in clinically dependent
individuals.
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Introduction
Cannabis is the most commonly used illicit drug
worldwide (UNODC, 2013). The European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA)
annual report notes that cannabis is the illicit drug most
likely to be used across Europe, with 11.2% of 15–34 year
olds reporting use in the last year (European Monitoring
Centre for Drugs and Drug Addiction, 2014). Routine
data collected by the US government shows that there
were a total of 300,000 admissions for cannabis use in
2012, making up 17.5% of admissions for substance
abuse in the US for that year (U.S Department of Health
and Human Services, 2014).
Not all cannabis use is problematic, but harm is most
likely in weekly and daily users (Davis, Thomas,
Jesseman, & Mazan, 2009). Cannabis dependence,
defined by the International Classification of Disorders
(ICD-10) as ‘‘a cluster of physiological, behavioural, and
cognitive phenomena in which the use of cannabis takes
on a much higher priority for a given individual than
other behaviours that once had greater value’’ can
develop from frequent use (World Health Organization,
2000). Not all individuals who use cannabis frequently
develop dependence; it is not clear why some individuals
develop dependence while others do not (van der Pol
et al., 2013). The quantity of cannabis consumed per day
and the level of harm sustained should be taken into
account when ascertaining if an individual is dependent,
and not just frequency of use (Asbridge, Duff, Marsh, &
Erickson, 2014). Different interventions may be applic-
able depending on whether or not an individual is at risk
of dependence; screening tools, such as The Alcohol,
Smoking and Substance Involvement Screening Test
 2015 British Crown Copyright. Published by Taylor & Francis.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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(ASSIST), recommend that those at moderate risk
receive a ‘‘brief intervention’’, while those at high risk
receive an ‘‘intensive intervention’’ (WHO ASSIST
Working Group, 2002).
Psychosocial and psychological interventions are used
in clinical practice to treat individuals who regularly use
cannabis (National Institute for Health and Care
Excellence (NICE), 2007). Interventions, such as
Cognitive Behavioural Therapy (CBT), motivational
interviewing (MI) and contingency management, aim
to change an individual’s behaviour through either
changing the way the individual thinks or behaves
(CBT), improving motivation to change and resolving
ambivalence to change (MI) or providing individuals
with tangible rewards (such as monetary vouchers) to
reinforce behaviour change (contingency management).
A number of systematic reviews have been undertaken
to assess the benefits of psychological and psychosocial
interventions for regular cannabis users (Davis et al.,
2015; Denis, Lavie, Fatseas, & Auriacombe, 2006; Dutra
et al., 2008). All have found some positive effects of such
interventions on cannabis users, but have only included a
subset of the available evidence, for example, only
including RCTs with non-active control conditions
(Davis et al., 2015), non-intensive treatments (Dutra
et al., 2008) or only individuals meeting the diagnostic
criteria for cannabis dependence (Denis et al., 2006;
Dutra et al., 2008).
The aim of this review is to assess the evidence for the
effectiveness of a broad range of psychosocial and
psychological interventions for cannabis cessation in
adults.
Methods
Literature search and inclusion criteria
In February 2014, searches of electronic databases (listed
in Box 1) were undertaken. Search terms are available on
request. Additional search methods included checking
references within relevant reviews and studies (reference
tracking) and contact with experts. Inclusion and
exclusion criteria are listed in Box 2.
Data extraction and quality assessment
Titles and abstracts were screened by one reviewer and a
10% sample checked by a second reviewer. Full texts
were screened by two reviewers. Data extraction was
undertaken by one reviewer and checked by a second
reviewer; any disagreements were resolved through
discussion. Where studies comprised duplicate reports,
the most recent and relevant report was used as the main
source.
Two reviewers independently assessed the methodo-
logical quality of each study and discrepancies were
resolved through discussion. Quality was assessed using
an adapted version of the Cochrane Collaboration risk of
bias assessment criteria. Two adaptations were made to
these criteria. Firstly, the ‘‘5-and-20 rule’’ was utilised for
incomplete outcome data – a level of risk was allocated
to participant attrition, either being low risk (55%
attrition), intermediate risk (5–20%) or high risk (420%)
(Schulz & Grimes, 2002). Attrition at the final follow-up
was used to assign a level of risk in studies with multiple
follow-up points. The second adaptation was to add an
‘‘overall risk’’ criterion, where studies were categorised
using the following criteria: ‘‘Low-risk’’ was allocated to
studies where randomisation, allocation concealment,
Box 1. Electronic databases
 MEDLINE
 EMBASE
 Cochrane Controlled Trials Register (CCTR)
 Health Technology Assessment (HTA) database
 Database of Abstracts of Reviews of Effects (DARE)
 Cochrane Systematic Reviews Database (CDSR)
 NHS Economic Evaluation Database (NHS EED)
 PsycInfo
 Web of Science Conference Proceedings Citation Index (WoS CPCI-S, WoS
CPCP-SSH)
 ClinicalTrials.gov
 metaRegister of Controlled Trials (mRCT)
Box 2. Inclusion exclusion criteria
Inclusion criteria Exclusion criteria
(1) RCT design (1) Based within the criminal justice setting (e.g. parole or prison)
(2) Included, in the majority (i.e. over 50%), adults aged 18 years or over who
were users of cannabis
(2) Involved providing interventions to an individual other than the
regular cannabis user (e.g. partner or parent)
(3) Tested a psychological or psychosocial intervention against comparator(s)
(excluding pharmacological comparators)
(3) Undertaken within a sub-specific population (i.e. indigenous com-
munities or HIV positive individuals)
(4) Provided data relating to individuals’ cannabis usage (where studies involved
participants with multiple drug dependencies, studies were included if they
reported cannabis use outcomes for the cannabis using population)
(4) Aimed to treat the participant’s psychological condition rather than
their cannabis use in ‘‘dually diagnosed’’ patients (i.e. patients with
both a psychiatric condition and cannabis dependence)
(5) Published in a peer-reviewed journal (5) Delivered the intervention, or a component of the intervention,
within an inpatient setting (i.e. study participants are resident within
a ward or treatment facility)
(6) Written in languages other than English
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blinded outcome assessment and incomplete data were
all determined to be ‘‘low risk’’. ‘‘High-risk’’ was
allocated to studies deemed to have undertaken inad-
equate randomisation (e.g. self-selection, sequential
patients), and/or where allocation was not concealed,
and/or where incomplete data was deemed to be ‘‘high
risk’’. ‘‘Unclear risk’’ was allocated to all other studies.
These criteria were added to reduce the subjectivity of
the Cochrane tool, in order to increase the reliability of
the tool when used by two researchers, and to provide an
overall picture of the risk of bias for each study.
Data synthesis
Data were analysed via a narrative synthesis, based
around grouping and tabulating the data in meaningful
clusters, allowing results to be summarised to provide an
overview of the direction of effect for each relevant
subgroup (Popay et al., 2006). Studies were categorised
according to their intervention and comparison groups
(e.g. CBT versus wait-list, CBT versus MI, etc.). Results
were tabulated for two key time points (post-treatment
and latest follow-up). The latest follow-up time point was
selected as the majority of trials did not utilise the same
follow-up time points; selecting the latest follow-up
provided information regarding the long-term effect of
the interventions. Effect sizes and corresponding confi-
dence intervals were included in the synthesis when
reported by the studies. Where reported, Cohen’s D effect
sizes were classified as small (threshold of d¼ 0.20),
medium (d¼ 0.50), large (d¼ 0.80), or very large
(d¼ 1.30) using the thresholds as described by Rosnow
and Rosenthal (1996). In order to synthesise the data, key
outcomes were selected which were both clinically
relevant and reported by the majority of studies.
Results
The searches identified 1087 citations. In total, 33 articles
relating to 25 RCTs were included in this review. The full
PRISMA flow chart is shown in Figure 1.
Description of studies contributing to data
synthesis
Table 1 gives an overview of the characteristics of the
included studies. Studies were undertaken in a range of
countries and recruited a total of 7938 participants.
Interventions varied considerably; single interventions
consisted of multiple and overlapping components. Ten
studies assessed CBT (versus wait-list, MI, or another
intervention), five studies assessed contingency manage-
ment (versus CBT or another intervention), nine studies
mainly assessed MI (versus wait-list or another inter-
vention) and one assessed web-based counselling.
All the included RCTs measured the effect of the
intervention(s) on participant’s cannabis usage,
although, the way in which this was measured varied
greatly by study. Eleven studies measured participants’
severity of cannabis dependence (measured via self-
report using various instruments, most frequently using
the Severity of Dependence Scale (SDS) or Addiction
Severity Index (ASI) (McLellan, Luborsky, Woody, &
O’Brien, 1980; Swift, Copeland, & Hall, 1998). Fourteen
studies measured participants’ number of cannabis
related problems (measured using various instruments,
including the Cannabis Problems Questionnaire (CPQ)
(Copeland, Gilmour, Gates, & Swift, 2005). Nineteen
studies measured participant’s usage of the intervention
or session attendance. For the narrative synthesis,
outcomes were grouped into four groups: cannabis
usage, severity of dependence, number of dependence
symptoms and number of cannabis problems.
Quality assessment
Most studies used an appropriately generated random-
isation sequence, with 17 studies being deemed ‘‘low
risk’’, seven ‘‘unclear risk’’, and one ‘‘high risk’’ for this
measure. No studies blinded study participants to group
allocation; we deemed this form of blinding to be
impossible for the interventions under review. As many
of the outcome measures were self-reported, outcomes
were deemed to have been blinded if the outcome
assessors were blinded to group allocation. This form of
blinding was poorly reported – in 14 studies, blinding of
outcome assessment was unclear or unreported.
Participant attrition was well reported but high, ranging
from 6% to 79% (mean 31%, median 25%); 17 studies
were rated as high risk for this attribute (with attrition of
more than 20% at the final follow-up time point).
Regarding overall risk, 18 studies were deemed to be
‘‘high risk’’, in seven studies the risk was unclear and no
studies were deemed to be ‘‘low risk’’.
Effectiveness of psychological and psychosocial
treatments
Tables 2 and 3 summarise the studies included in the
seven comparison groups, including interventions and
between group differences at post-treatment (Table 2)
and follow-up (Table 3).
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CBT versus wait-list control
Six studies (Babor et al., 2004; Copeland, Swift, Roffman,
& Stephens, 2001; Hoch et al., 2012, 2014; Jungerman,
Andreoni, & Laranjeira, 2007; Stephens, Roffman, &
Curtin, 2000) compared CBT (4–14 sessions) versus
wait-list control. Five (Babor et al., 2004; Copeland et al.,
2001; Hoch et al., 2012, 2014; Jungerman et al., 2007)
provided individual CBT sessions and one (Stephens
et al., 2000) group sessions. CBT interventions also
incorporated other components including case manage-
ment (Babor et al., 2004) and a social support group
(Stephens et al., 2000). The majority of studies only
included participants who met the Diagnostic and
Statistical Manual of Mental Disorders (DSM) criteria
for cannabis dependence (Babor et al., 2004; Copeland
et al., 2001; Hoch et al., 2012; Stephens et al., 2000). The
remaining studies included participants who used can-
nabis a certain number of times a month (Hoch et al.,
2014; Jungerman et al., 2007).
Five studies (Babor et al., 2004; Hoch et al., 2012,
2014; Jungerman et al., 2007; Stephens et al., 2000)
reported post treatment (5–18 weeks) outcomes. All five
reported significantly better results for CBT (4–14
sessions) than for wait-list on all key outcomes (cannabis
usage, severity of dependence, dependence symptoms,
and cannabis problems). Effect sizes were small to very
large where reported. Full intervention session attend-
ance ranged from 65% (Hoch et al., 2014) to 86% (Hoch
et al., 2012).
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Figure 1. Study selection process – Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Only one study (Copeland et al., 2001) reported
between-group data at a later follow-up (9 months)
point than post-treatment. This study reported signifi-
cantly better results for CBT (six sessions) than wait-list
on all key outcomes at 9 months post-baseline except days
used (p NR).
CBT or psychotherapy versus brief MI
Four studies (Babor et al., 2004; Budney, Higgins,
Radonovich, & Novy, 2000; Copeland et al., 2001;
Stephens et al., 2000) compared CBT (6–14 sessions)
versus brief MI/MET (1–4 sessions). Three studies
(Babor et al., 2004; Budney et al., 2000; Copeland
et al., 2001) provided individual CBT sessions while one
(Stephens et al., 2000) compared group CBT against
individual MET. CBT interventions also included case
management (Babor et al., 2004) and a social support
group (Stephens et al., 2000). All studies included only
participants who met the DSM criteria for cannabis
dependence.
Three CBT studies reported between group data post-
treatment (at 12–18 weeks). One study (Babor et al.,
2004) reported significant between group differences,
finding that 9-session CBT was significantly better than
2-session MET on most key outcomes (all except joints
per day), with small to medium effect sizes (d¼ 0.4–0.5,
for days used and dependence symptoms). Full inter-
vention session attendance ranged from 69% (Copeland
et al., 2001) to 86% (Stephens et al., 2000).
Three studies reported between group data at later
follow-ups. Results were mixed, with significant differ-
ences identified in cannabis usage outcomes in one study
(Babor et al., 2004) at 9 and 15 months, but not at 9
months (Copeland et al., 2001) or 16 months (Stephens
et al., 2000) in the other two studies. A significant
difference was found between groups in the one study
that reported severity of dependence at 9 months
(p¼ 0.04) (Copeland et al., 2001) and dependence
symptoms at 9 months (p50.01, d¼ 0.31) (Babor
et al., 2004), but no significant differences were found
when measured at 16 months in another study (Stephens
et al., 2000). All three studies that reported cannabis
problems found no significant between group differences
at 9 months (Babor et al., 2004; Copeland et al., 2001), 15
months (Babor et al., 2004) or 16 months (Stephens
et al., 2000).
CBT versus other interventions (or different CBT
format or duration)
Four studies (Jungerman et al., 2007; Kadden, Litt,
Kabela-Cormier, & Petry, 2007; Sobell, Sobell, &
Agrawal, 2009; Stephens, Roffman, & Simpson, 1994)
compared CBT (4–10 sessions) against another inter-
vention, comprising a social support group (Stephens
et al., 1994), case management sessions (Kadden et al.,
2007) or compared individual versus group CBT (Sobell
et al., 2009) or CBT over different durations (Jungerman
et al., 2007). One study only included participants who
met the DSM criteria (Kadden et al., 2007), while two
included participants who consumed cannabis at a
certain frequency (Jungerman et al., 2007; Stephens
et al., 1994) and one study included individuals without
‘‘severe dependence’’ (Sobell et al., 2009). All four studies
showed no significant between group differences at post-
treatment for cannabis usage outcomes, but showed
mixed results for cannabis problems and severity of
dependence outcomes, with the same study (Jungerman
et al., 2007) showing significant results for each. The
same study also identified significant differences for
dependence symptoms outcomes. Two studies reported
average number of sessions attended across both study
groups, reporting 76% (Stephens et al., 1994) and 58%
(Kadden et al., 2007) attendance, with no significant
differences between groups. At later follow-up points,
no significant differences were identified for any key
outcomes at 14 or 15 months.
Telephone or web-based CBT or counselling versus
wait-list or other interventions
Three studies (Gates, Norberg, Copeland, & Digiusto,
2012; Rooke, Copeland, Norberg, Hine, &
McCambridge, 2013; Tossmann, Jonas, Tensil, Lang, &
Struber, 2011) compared telephone or web-based inter-
ventions versus wait-list or education controls.
Interventions included telephone-CBT (Gates et al.,
2012), web-CBT (Rooke et al., 2013) and web-counsel-
ling (Tossmann et al., 2011). One study included
participants only if they met the DSM criteria for
cannabis dependence (Tossmann et al., 2011), while two
included participants based on their cannabis intake
(Gates et al., 2012; Rooke et al., 2013).
Two studies measured outcomes at post-treatment
time points (Gates et al., 2012; Rooke et al., 2013). Mixed
results were identified for cannabis use outcomes, with
significant reductions in usage for a 6 week CBT/MI
intervention, with a small effect size (d¼ 0.30) (Rooke
et al., 2013), and significant reductions in joints per day
for a 3 week telephone CBT/MI intervention (Gates
et al., 2012). Other cannabis use outcomes in the same
two studies reported insignificant results (Gates et al.,
2012; Rooke et al., 2013). The effect of web or telephone
interventions on severity of dependence was mixed, with
one study showing a significant improvement (Gates
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et al., 2012) and another showing insignificant results
and small effect (d¼ 0.30) (Rooke et al., 2013). One
study reported the effect on cannabis problems and
reported a significant decrease (Gates et al., 2012).
All three studies reported telephone or web session
completion, reporting 51% (Tossmann et al., 2011), 58%
(Rooke et al., 2013) and 81% (Gates et al., 2012)
attendance.
All three studies reported follow-up outcomes at
3 months. Cannabis usage outcomes were mixed,
with some significant improvements in two studies
providing 6–7 week interventions (Rooke et al., 2013;
Tossmann et al., 2011), but no significant improve-
ments in a study providing a 3 week intervention
(Gates et al., 2012). Severity of dependence outcomes
followed a similar pattern to that at post-treatment.
Improvements in cannabis problems were significant in
the one study reporting such outcomes (Gates et al.,
2012).
Brief MI versus wait-list or assessment only
Ten studies (Babor et al., 2004; Copeland et al., 2001;
de Dios et al., 2012; Gmel, Gaume, Bertholet, Fluckiger,
& Daeppen, 2013; Humeniuk et al., 2012; Lee,
Neighbors, Kilmer, & Larimer, 2010; Lee et al., 2013;
Stein, Hagerty, Herman, Phipps, & Anderson, 2011;
Stephens, Roffman, Fearer, Williams, & Burke, 2007;
Stephens et al., 2000) compared a brief intervention (1–2
sessions of MET, MI or personalised feedback) versus
wait-list or assessment only. One study assessed a web-
based intervention (personalised feedback) (Lee et al.,
2010). One study provided a group MI session (Gmel
et al., 2013) while the other nine provided individual
sessions. Three studies included participants only if they
met the DSM criteria for cannabis dependence (Babor
et al., 2004; Copeland et al., 2001; Stephens et al., 2000)
while four studies included participants who consumed a
certain quantity of cannabis per month (1–15 d used per
month) (de Dios et al., 2012; Lee et al., 2013; Stein et al.,
2011; Stephens et al., 2000), while this was not reported
in two studies (Gmel et al., 2013; Humeniuk et al., 2012).
Five studies implemented an upper age limit for study
inclusion, ranging from 19 to 29 years (de Dios et al.,
2012; Gmel et al., 2013; Lee et al., 2010, 2013; Stein et al.,
2011).
Five studies reported between-group data post-
treatment, showing a mixed picture with some signifi-
cant effects. Cannabis use outcomes largely showed
significant improvements, with all studies reporting at
least one significant outcome. Effect sizes (reported in
one study) were small to medium (d¼ 0.29–0.59) (Babor
et al., 2004). Three studies reported dependence
symptoms, identifying a significant improvement
(Babor et al., 2004; Stephens et al., 2000, 2007) but a
small to medium effect size in the one study that
reported effect sizes (Babor et al., 2004). Three studies
reported the effect on cannabis problems, with
one reporting a significant effect (Stephens et al.,
2000). Eight studies (Babor et al., 2004; Copeland et al.,
2001; de Dios et al., 2012; Humeniuk et al., 2012;
Lee et al., 2013; Stein et al., 2011; Stephens et al., 2000,
2007) reported session attendance, ranging from 80% to
100%.
At later follow-ups, seven studies reported mixed
between-group results, with some significant effects.
Cannabis use outcomes were mixed; studies reporting at
shorter follow-up time-points (3 months) were more
likely to report significant between group differences
that those reporting long-term outcomes (6–9 months).
One study reported RRs (risk ratios) at 3 and 6 months,
showing reduced RR of cannabis usage at 3 months
(RR¼ 0.96 and 0.76) but increased risk at 6 months
(RR¼ 1.11) (Lee et al., 2013). One study reported
significant improvements in severity of dependence
at 9 months (Copeland et al., 2001). Three studies
reported participant’s cannabis problems between 3 and
9 months, with significant results reported in one study
(Copeland et al., 2001).
Brief MI versus other interventions
Three studies (Fernandes et al., 2010; Fischer, Jones,
Shuper, & Rehm, 2012; Stephens et al., 2007) compared a
brief intervention (one session of MI or telephone MI)
versus education controls (regarding cannabis or general
health). All MI sessions were individual (not group).
Two studies selected participants who used cannabis a
certain number of days/uses per week (Fischer et al.,
2012; Stephens et al., 2007); this was not reported in one
study (Fernandes et al., 2010).
One study (Stephens et al., 2007) of MI (one session)
versus education control reported post treatment out-
comes, reporting significant improvements in cannabis
usage, dependence and cannabis problems outcomes.
The same study reported session attendance, where 89%
of participants attended a MI session and 94% attended a
‘‘cannabis education’’ session.
At later follow-ups, all three studies reported cannabis
use outcomes at time points ranging from 3 to 12
months, with one finding a significant result at 6 months
(OR¼ 1.6) (Fernandes et al., 2010). One study reported
both dependence symptoms and cannabis problems at 6
and 12 months, finding a significant decrease in
dependence symptoms at both time points, but no
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significant differences in cannabis problems (Stephens
et al., 2007).
Contingency management (vouchers for absti-
nence) versus other interventions
Five studies (Budney, Moore, Rocha, & Higgins, 2006;
Budney et al., 2000, 2011; Kadden et al., 2007; Litt,
Kadden, & Petry, 2013) compared contingency manage-
ment (vouchers for abstinence assessed via urine tests),
alone or in combination with CBT, versus other
interventions. One study also assessed computer-based
CBT plus contingency management (Budney et al.,
2011). Comparators included CBT (Budney et al., 2000,
2006; Kadden et al., 2007) (9–14 sessions), MET (Budney
et al., 2000, 2011) (2–4 sessions), case management
(Kadden et al., 2007; Litt et al., 2013) (nine sessions) and
CBT+ vouchers (CBT plus vouchers for abstinence) for
completed CBT homework (Litt et al., 2013). All studies
included cannabis users only if they met the DSM
criteria for cannabis dependence.
Four studies reported between-group data post-treat-
ment; results favoured either CBT+ vouchers or vou-
chers alone over CBT alone. Cannabis use outcomes
showed a majority of significant differences between
groups, with the results favouring either CBT+ vouchers
or vouchers alone over CBT alone. One study reported
effect sizes for 6 weeks or more of continuous abstinence,
which favoured vouchers over CBT and CBT plus
vouchers over CBT alone (Budney et al., 2006). One
study reported cannabis problems, and another reported
severity of dependence, both reporting non-significant
differences between contingency management and other
interventions (Budney et al., 2006, 2011). Session
attendance was reported by two studies and was similar
between interventions, ranging from 61% to 69%
(Budney et al., 2006; Litt et al., 2013).
Later follow-ups indicated that positive results were
maintained for combined treatment with
CBT+ vouchers. However, the beneficial short-term
results for vouchers alone were less likely to be
maintained long-term. Four studies reported between-
group data at 14–15 months, with all four reporting
cannabis use outcomes, the majority of which were not
significantly different between groups (Budney et al.,
2006, 2011; Kadden et al., 2007; Litt et al., 2013). Severity
of dependence and dependence symptoms were reported
at 14 months in one study comparing case management,
contingency management and CBT, finding no signifi-
cant differences between groups (Kadden et al., 2007).
Two studies found no significant differences between
groups for cannabis problems at 12 and 14 months
(Budney et al., 2006; Kadden et al., 2007).
Discussion
Across six studies of CBT (4–14 sessions) versus wait-
list, CBT was significantly better on most outcomes
(cannabis use, severity of dependence, cannabis prob-
lems), post-treatment (in all five studies with data) and
at 9 months (in the one study with later follow-up). Four
studies comparing CBT (6–14 sessions) against briefer
MI/MET (1–4 sessions) gave mixed results, with two
studies showing better results for CBT post-treatment
and at 9–16 months, while two further studies showed
few between-group differences; both CBT and MI gave
significant improvements from baseline. One study of
CBT versus social support group (10 sessions each) and
another of CBT versus case management (nine sessions
each) showed no significant differences between groups
but all groups significantly improved from baseline with
changes maintained at 14–15 months. One study each of
telephone-CBT, web-CBT and web-counselling all
showed significant improvements over wait-list or edu-
cation control post-treatment and at 3 months. Ten
studies assessing brief MI/MET (1–2 sessions) versus
wait-list or assessment only (AO) gave mixed results,
with brief MI appearing significantly better on some
outcomes but not others, post-treatment and at 3–9
months. Results were similar for three studies comparing
brief MI against education controls. Compared with
studies assessing other interventions, those assessing
brief MI tended to include younger participants due to
six of the 13 studies (de Dios et al., 2012; Fischer et al.,
2012; Gmel et al., 2013; Lee et al., 2010, 2013; Stein et al.,
2011) implementing an upper age limit for study
inclusion, ranging from 19 to 29 years. Five studies
assessed contingency management (monetary vouchers
for abstinence) in a clinically dependent population.
Vouchers alone and CBT plus vouchers gave better
results than CBT or MET alone post-treatment (three
studies), while at 14–15 months positive results were
maintained for CBT plus vouchers but less so for
vouchers alone (two studies). A minority of the studies
(n¼ 9) reported effect sizes for between group differ-
ences at post-treatment, and five studies reported such
figures at later outcome assessments.
This review is inclusive in scope, including a wide
range of studies, interventions and outcomes. Only RCTs
were included, resulting in only the highest level
evidence being analysed. This inclusivity resulted in a
number of limitations. First, the inclusivity of studies
resulted in the reporting of a diverse and heterogeneous
group of outcomes. Peters, Nich and Carroll (2011)
suggest a framework for evaluating outcomes in RCTs of
cannabis cessation therapies, suggesting that frequency
of cannabis use, severity of cannabis use, and
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psychosocial functioning provide the best model of end
of treatment outcomes (Peters et al., 2011). In this
review, we presented all key outcomes reported by the
included studies, grouped into four categories (cannabis
use, severity of dependence, dependence symptoms, and
cannabis problems). Second, many studies did not report
between group differences at post-treatment or follow-
up, instead reporting change from baseline in each
group, thus limiting the comparison that can be made
between treatments. Those that did report between
group differences did not always report effect sizes. The
studies that did report effect sizes only report confidence
intervals in the minority of cases. Finally, the inclusion
criteria used to recruit participants into the studies were
diverse. The majority of studies that assessed CBT
recruited participants who met the DSM criteria for
cannabis dependence, while other studies, assessing
other interventions, recruited those who utilised canna-
bis a certain frequency per month. Therefore, currently
we can only assess the effectiveness of CBT on ‘‘clinically
dependent’’ individuals, and other interventions on
individuals who may not be dependent on cannabis
and have a wide range of cannabis usage.
To our knowledge, this is the first review that has
attempted to synthesise all evidence regarding available
psychological and psychosocial treatments for cannabis
cessation. Other systematic reviews have included a
similar set of studies, but have undertaken a meta-
analysis. The most recent of which undertook a meta-
analysis of 10 studies, two of which were not included in
this review (due to participants being referred via the
criminal justice setting in one study) (Sinha, Easton,
Renee-Aubin, & Carroll, 2003), and the study not
reporting outcomes for marijuana using population
only in another (Davis et al., 2015; Roffman, Stephens,
Simpson, & Whitaker, 1988). Behavioural therapies
outperformed control conditions when all outcome and
time variables were combined (Hedges’ g¼ 0.44). Dutra
et al. reviewed psychosocial interventions for cannabis
dependence, including five studies that included regular
cannabis users, two of which were not included in this
review (due to participants being referred via the
criminal justice setting in one study (Carroll et al.,
2006) and participants being, on average, less than 18
years of age in another (Martin & Copeland, 2008),
finding a large effect on cannabis use (d¼ 0.81, 95%
CI¼ 0.25–1.36)). The present review did not identify
conclusive evidence to support these findings. Meta-
analysis, although providing clinically relevant estima-
tions of effect sizes, is not always relevant, especially
when undertaken on a set of heterogeneous studies
(Higgins & Green, 2011). Although studies in this review
were grouped by intervention and comparator, there was
still considerable variation within the groups. The most
notable heterogeneity within each comparison group
within this review was the length and frequency of the
intervention, the outcomes measures and follow-up time
points. The present review did not include a number of
studies included in previous reviews. This possibly
limited the scope for undertaking meta-analyses, but
did prevent further heterogeneity from being present in
the data.
Future studies should carefully consider trial meth-
odology. Many studies in the present review either did
not follow up participants at post-treatment or later
follow-ups, or did not undertake between group infer-
ences at these time points. Studies should follow up
patients beyond treatment cessation, and may wish to
include an inactive control arm. Wait-list controls with
long-term follow-up are also valuable, although this
needs to be balanced against ethical considerations and
acceptability to trial participants.
Conclusions
This systematic review has identified a disparate evi-
dence base that differed most notably in the nature and
length of the interventions, the comparator groups, the
populations studied and the outcomes measured (differ-
ing in metrics used, statistics reported, and follow-up
periods). There was a distinct lack of between group
comparisons at long-term follow-up time points.
Individuals recruited to the trials differed considerably
in their cannabis use at baseline, with a cohort of trials
(involving mostly CBT and contingency management
interventions) requiring individuals to meet the DSM
criteria for cannabis dependence. Based on the available
evidence, courses of CBT improved outcomes in a self-
selected population of cannabis users who are clinically
dependent, although there is a lack of evidence to
support the long-term effect of such interventions. Brief
MI improved outcomes at post-treatment in a younger
non-clinically dependent population, but this was not
sustained in the long term (3–12 months). There is some
evidence that CBT (6–14 sessions) may be more effective
than briefer MI interventions although results were
mixed. Contingency management may also enhance
long-term outcomes in combination with CBT in a
clinically dependent population. Intervention retention
varied within comparison groups, although brief MI
sessions appeared to have the highest attendance.
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